版本:
中国

BRIEF-Braeburn Pharma submits application to market opioid implant in Canada

June 13 Knight Therapeutics Inc

* Braeburn pharmaceuticals and knight therapeutics announce filing of new drug submission for probuphine(r) in canada for opioid drug dependence

* Knight therapeutics - been accepted for review by health canada for probuphine (buprenorphine subdermal implant) for treatment of opioid drug dependence Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐